Dyspnea Over- and underweight based on BMI Right ventricular abnormalities (wall motion abnormalities, reduced function, increased volumes, or known scarring/fat deposition). I50.9 I40.9 I27.0
Conditions
Interventions
Group 1: Patients presenting with the primary symptom of dyspnea and an existing indication for cardiovascular magnetic resonance imaging (MRI) will additionally undergo lung function sequences during
Sponsors
Charite - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -Written informed consent of the patient before the start of study-specific procedures -Patient is capable of giving consent and able to understand the nature and scope of the clinical trial -Age = 18 years -Clinically relevant dyspnea -Fulfillment of at least one of the inclusion criteria of the specified subgroups: -Patients with underweight, overweight, or obesity defined according to BMI as follows: Underweight = BMI 40 -Patients with reduced systolic ventricular function defined as follows: Reduced left ventricular function = ejection fraction < 40% Moderately reduced left ventricular function = ejection fraction 40–50% -Patients with chronic pulmonary underlying diseases, including bronchial asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension (PAH) -Patients with acute or chronic myocarditis -Patients with systemic diseases involving the heart, in particular cardiac sarcoidosis -Patients with right ventricular abnormalities (wall motion abnormalities, reduced function, increased volumes, or known scarring/fat deposition) -Patients with moderate to severe stenosis or insufficiency of the heart valves -Indication for CMR is present
Exclusion criteria
Exclusion criteria: -Absolute contraindication for an MRI examination -Known allergy to MRI contrast agents -Chronic renal insufficiency with GFR < 30 ml/min (according to CKD-EPI) -Patients who have already participated in this study -Pregnancy or breastfeeding -Refusal by the participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular outcome (major adverse cardiac events (MACE)), consisting of myocardial infarction, stroke, cardiovascular death, and hospitalization for heart failure, assessed after 2 years using a standardized questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Association between lung perfusion (defined as percentage perfusion deficits) and ventilation (defined as percentage ventilation deficits) and quality of life (defined based on standardized questionnaires) -Association between lung perfusion and ventilation and left ventricular function | — |
Countries
Germany
Contacts
Public ContactJeanette Schulz-Menger
Charite - Universitätsmedizin Berlin
Outcome results
None listed